Kronos Bio (KRON) has entered into a definitive merger agreement with Concentra Biosciences, LLC, whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock, plus one non-tradeable contingent value right.
The Kronos Bio Board has determined that the acquisition by Concentra is in the best interests of all Kronos Bios hareholders and has approved the Merger Agreement and related transactions. A wholly owned subsidiary of Concentra will commence a tender offer by May 15, 2025 to acquire all outstanding shares of Kronos Bio Common Stock.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.